Nephros Inc. filings document formal disclosures for a water technology company selling filtration solutions to medical and commercial markets. Recent 8-K reports furnish operating results and financial condition updates, Regulation FD presentations, and material event disclosures tied to the company's product, service, and education strategy.
The filing record also includes a material definitive agreement with Medica S.p.A. covering license and supply arrangements for filtration products based on Medisulfone ultrafiltration technology. These disclosures describe contractual rights, supply obligations, product commercialization arrangements, and related public-company reporting matters.
Nephros, Inc. has scheduled its virtual annual meeting for November 25, 2026, at 11:00 a.m. Eastern Time. Stockholders will vote on Robert Banks and Joseph Harris for two director seats with terms ending in 2029, ratification of Baker Tilly US, LLP as auditor for fiscal 2026, an advisory vote on named executive compensation, and the frequency of future compensation votes. The Board recommends an annual compensation vote. Holders of common stock on September 30, 2026, are entitled to one vote per share; 10,870,004 shares were outstanding on that date.
Wexford-affiliated entities distributed all their Nephros shares on September 14, 2026, and Wexford’s director nomination and removal rights under the investor rights agreement terminated. Arthur H. Amron, originally nominated by Wexford, continues as a director. For fiscal 2025, reported total compensation was $627,125 for CEO Robert Banks and $322,617 for CFO Judy Krandel. Net income was $1,194,000 in 2025 versus $74,000 in 2024; audit fees were approximately $423,851 in 2025.
Nephros, Inc. (NEPH) scheduled its 2026 Annual Meeting of Stockholders for November 25, 2026, at 11:00 a.m. Eastern Time, to be held virtually by live webcast. Stockholders of record as of September 30, 2026 are entitled to notice of and to vote at the meeting.
The company set October 23, 2026 as the deadline for Rule 14a-8 proposals and Rule 14a-19 notices from stockholders seeking to solicit proxies for director nominees other than the company’s nominees. Notice of proposals not included in the proxy statement must also be received by that date for purposes of the company’s discretionary voting authority. The definitive proxy statement will provide the agenda and webcast instructions.
Nephros, Inc. (NEPH) is the subject of an Amendment No. 12 to a Schedule 13D filed by Wexford Capital LP and affiliated reporting persons. They now report beneficial ownership of 223,539 shares of common stock, representing 2.06% of Nephros’s outstanding shares as of August 7, 2026.
On September 14, 2026, Wexford Capital effected an in-kind distribution of certain Nephros shares from affiliated funds and vehicles to their underlying investors and sold additional shares to an entity controlled by Nephros director Arthur Amron, with proceeds distributed to underlying investors. The reporting persons state they ceased to be beneficial owners of more than five percent of Nephros common stock on that date.
Nephros, Inc. (NEPH) is reported to have 5%-plus ownership by Charles E. Davidson and CD Holding Company, LLC in a Schedule 13G. The Reporting Persons beneficially own 616,945 shares of common stock, representing 5.68% of the class, based on 10,860,120 shares outstanding as of August 7, 2026.
Davidson, a United States citizen, and CD Holding Company, LLC, a Delaware entity, report sole voting and sole dispositive power over 616,945 shares and no shared voting or dispositive power. Davidson may be deemed to beneficially own the shares held by CD Holding Company, LLC due to his status as a controlling person, and he has the right to receive dividends and sale proceeds from these shares.
NEPHROS INC (NEPH) received a Form 4 from Wexford Capital LP and related reporting persons, all listed as ten percent owners, reporting two indirect dispositions of common stock on September 14, 2026. One was an in-kind distribution of 3,355,111 shares from certain Wexford-managed entities that did not involve a purchase, sale, or additional consideration. The other was a sale of 22,710 shares at $3.95 per share from those entities to an entity controlled by director Arthur Amron, with proceeds distributed to underlying investors and no compensation to the selling entities. The reporting persons may be deemed to beneficially own shares held by the referenced funds but disclaim beneficial ownership except to the extent of their pecuniary interests, and no Rule 10b5-1 trading plan is reported.
NEPHROS INC (NEPH) director Arthur H. Amron and affiliated entity Amron Holdings LLC reported acquiring a total of 43,295 shares of common stock on September 14, 2026 in entity-restructuring transactions coded as “J”. Amron received 17,749 shares directly via an in-kind distribution from Wexford entities for no additional consideration, bringing his direct holdings to 158,623 shares.
Amron Holdings LLC acquired 2,836 shares through an in-kind distribution and 22,710 shares in a related sale from the Wexford entities at $3.95 per share, with sale proceeds distributed to underlying Wexford investors and no compensation to the Wexford entities. Arthur Amron, as controlling person of Amron Holdings, may be deemed to beneficially own the shares held by Amron Holdings and holds voting and dispositive power over them.
NEPHROS INC (NEPH) had insider activity reported by entities associated with Wexford Capital LP. On 2026-08-18, Wexford Capital exercised stock options to purchase 3,765 shares of common stock at an exercise price of $3.60 per share through a cashless exercise, with a portion of the option shares withheld to satisfy the exercise price. This resulted in the acquisition of 812 shares of common stock, bringing Wexford Capital’s direct common stock holdings to 56,872 shares and leaving 36,198 stock options outstanding, expiring on August 24, 2026. Wexford GP LLC, Charles E. Davidson and Joseph M. Jacobs may be deemed controlling persons of Wexford Capital and disclaim beneficial ownership except to the extent of any pecuniary interests. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares. He also holds stock options to acquire 7,323 shares of Common Stock at an exercise price of $2.14 per share that are fully vested, and additional options for 7,050 shares at an exercise price of $1.47 per share that vest in three equal installments of 2,350 shares on 1/1/25, 1/1/26 and 1/1/27.
Nephros, Inc. reported stronger results for the quarter and six months ended June 30, 2026. Q2 net revenue rose 36% to $6.0 million, and six‑month net revenue grew 21% to $11.2 million, driven mainly by programmatic product growth, commercial products, and higher service revenue.
Q2 net income increased to $1.2 million from $0.2 million a year earlier, while six‑month net income rose to $1.3 million from $0.8 million. Q2 gross margin expanded to 67%, aided by a $0.6 million IEEPA tariff refund recorded as a reduction of cost of goods sold; underlying costs faced pressure from a weaker U.S. dollar, higher shipping, and mix shift toward lower‑margin services and commercial offerings.
Cash and cash equivalents were $4.7 million with working capital of $10.3 million, and management believes existing cash and projected cash flows will fund operations for at least 12 months, despite $1.0 million of operating cash outflows in the first half from increases in receivables and inventory. The company highlights customer and supplier concentration, significant minimum purchase commitments under its Medica license and supply agreement, ongoing tariff headwinds, and discloses a material weakness in internal control over financial reporting as of June 30, 2026.
Nephros, Inc. reported strong results for the quarter and six months ended June 30, 2026. Second-quarter net revenue reached a record $6.0 million, up 36% from $4.4 million a year earlier, driven mainly by 27% growth in core programmatic product revenue and nearly tripled service revenue. Net income for the quarter rose to $1.2 million from $0.2 million, and Adjusted EBITDA increased to $1.3 million from $0.4 million.
Quarterly gross margin improved to 67% from 63%, helped by recognition of an approximately $0.6 million tariff refund under the International Emergency Economic Powers Act, recorded as a receivable and reduction of cost of goods sold. For the first half of 2026, net revenue was $11.2 million versus $9.3 million, and net income was $1.3 million versus $0.8 million. As of June 30, 2026, Nephros held about $4.7 million in cash and cash equivalents and remained debt free, with management highlighting its expanding recurring revenue base, growing service platform, and newer product offerings as key growth drivers.